Arnold Negrin
Psychiatry · Savannah, GANPI 1336186311
Payments from drug & device makers
Across 769 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Ironshore Pharmaceuticals Inc.$990
- Otsuka America Pharmaceutical, Inc.$915
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$712
- plus $6K from 25 others
What the payments were for
- Food & beverage$13,453100%
- Education$540%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 181 | $2,378 |
| Supernus Pharmaceuticals, Inc. | 111 | $1,616 |
| Vanda Pharmaceuticals Inc. | 50 | $1,180 |
| Ironshore Pharmaceuticals Inc. | 67 | $990 |
| Otsuka America Pharmaceutical, Inc. | 43 | $915 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $712 |
| Corium, LLC | 31 | $637 |
| Axsome Therapeutics, Inc. | 17 | $527 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $515 |
| Sunovion Pharmaceuticals Inc. | 26 | $460 |
| Neos Therapeutics, LP | 41 | $447 |
| Alkermes, Inc. | 25 | $440 |
| Tris Pharma Inc | 18 | $419 |
| Johnson & Johnson | 21 | $404 |
| Bausch Health US, LLC | 19 | $365 |
| Lundbeck LLC | 11 | $297 |
| Shire North American Group Inc | 8 | $247 |
| Teva Pharmaceuticals USA, Inc. | 4 | $168 |
| Jazz Pharmaceuticals Inc. | 4 | $155 |
| Idorsia Pharmaceuticals US Inc | 6 | $123 |
| Adlon Therapeutics L.p. | 7 | $116 |
| Noven Therapeutics, LLC | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Neuronetics, Inc. | 4 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$125
- AUSTEDO$122
- JORNAY PM$115
- SUNOSI$101
- Jornay PM 20mg capsules (Bottle of 100)$101
How this compares
$13,507 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 20 | $44,879 |
| Lisdexamfetamine Dimesylate | 15 | $3,799 |
| Atomoxetine Hcl | 19 | $2,863 |
| Aripiprazole | 20 | $1,027 |
| Bupropion XlBupropion Hcl | 34 | $580 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $507 |
| Hydroxyzine Hcl | 48 | $407 |
| Lamotrigine | 31 | $371 |
| Haloperidol Decanoate | 11 | $361 |
| Benztropine Mesylate | 21 | $291 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $281 |
| Alprazolam | 68 | $280 |
| Clonazepam | 33 | $271 |
| Sertraline Hcl | 47 | $237 |
| Risperidone | 21 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $1,180 | $44,87920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Savannah
- Michael MobleySavannah$2.9M
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.